Compound Information | SONAR Target prediction |
Name: | BUDESONIDE |
Unique Identifier: | SPE01500813 |
MolClass: | Checkout models in ver1.5 and ver1.0 |
Molecular Formula: | |
Molecular Weight: | 396.264 g/mol |
X log p: | 3.817 (online calculus) |
Lipinksi Failures | 0 |
TPSA | 52.6 |
Hydrogen Bond Donor Count: | 0 |
Hydrogen Bond Acceptors Count: | 6 |
Rotatable Bond Count: | 4 |
Canonical Smiles: | CCCC1OC2CC3C4CCC5=CC(=O)C=CC5(C)C4C(O)CC3(C)C2(O1)C(=O)CO |
Source: | semisynthetic |
Therapeutics: | antiinflammatory |
Generic_name: | Budesonide |
Drug_type: | Approved Drug |
Pharmgkb_id: | PA448681 |
Kegg_compound_id: | C06858 |
Drugbank_id: | APRD00442 |
Melting_point: | 221-232 oC |
H2o_solubility: | insoluble |
Logp: | 3.145 |
Cas_registry_number: | 51333-22-3 |
Drug_category: | Bronchodilator Agents; Anti-inflammatory Agents; Corticosteroids; ATC:A07EA06; ATC:D07AC09; ATC:R01AD05; ATC:R03BA02 |
Indication: | For the treatment of mild to moderate active Crohn-s disease. |
Pharmacology: | Budesonide is a synthetic corticosteroid indicated for the treatment of mild to moderate active Crohn-s disease involving the ileum and/or the ascending colon. Budesonide is used in Crohn-s disease to decrease the symptoms and inflammation associated with the disease, especially at times of flare up. Budesonide has a high topical glucocorticosteroid (GCS) activity and a substantial first pass elimination. The formulation contains granules which are coated to protect dissolution in gastric juice, but which dissolve at pH >5.5, ie, normally when the granules reach the duodenum. Thereafter, a matrix of ethylcellulose with budesonide controls the release of the drug into the intestinal lumen in a time-dependent manner. |
Mechanism_of_action: | The exact mechanism of action of budesonide in the treatment of Crohn-s disease is not fully understood. However, being a glucocorticosteroid, budesonide has a high local anti-inflammatory effect. |
Organisms_affected: | Humans and other mammals |